STATEMENT OF ROBERT WEISSMAN, CO-DIRECTOR, ESSENTIAL ACTION ON THE CAFTA NEGOTIATIONS AND ACCESS TO MEDICINES


The United States Trade Representative has forced down the throats of Central American countries enhanced patent protections. If the Bush administration succeeds in ramming the agreement through the U.S. Congress, the result will be that people die.

USTR should today be ashamed, rather than crowing.

By prioritizing the super-profit demands of Big Pharma over public health imperatives, USTR has ignited an additional group of opponents of CAFTA in Congress.

The actual CAFTA text remains secret -- secret only from the public; negotiators and business know what has been agreed on -- but all indications are that USTR has achieved the Big Pharma agenda of demanding a range of provisions that will delay the entry of price-lowering generic competition for medicines. These provisions include:

There is no defensible reason to include intellectual property rules in CAFTA. All negotiating countries are members of the WTO, and bound by its intellectual property rules. All agreed to the Doha Declaration on the TRIPS Agreement and the Public Health, requiring countries to implement the WTO agreement in a fashion that would "protect public health and, in particular, promote access to medicines for all." Inclusion of IP in CAFTA can only mean countries will be more protective of Big Pharma's interest, at the expense of expedited introduction of price-lowering generic competition, and at the expense of their obligations under the Doha Declaration.

Essential Action is a Washington, D.C. corporate accountability group. It focuses on intellectual property and global health issues.


Return to: CPTech Home -> Main IP Page -> IP and Healthcare -> Trade Page -> CAFTA